SCHEDULE: Biogen Completes Apellis Pharmaceuticals Acquisition
Acquisition Completion Filing
Biogen Inc. has finalized its acquisition of Apellis Pharmaceuticals, Inc. through a tender offer and subsequent merger, marking an exit filing for Biogen.
Summary
- Biogen Inc. has completed the acquisition of Apellis Pharmaceuticals, Inc. via a tender offer and a subsequent merger.
- The tender offer, which commenced on April 14, 2026, offered $41.00 in cash per share plus a contingent value right (CVR) of up to $4.00 per share.
- On May 14, 2026, Biogen accepted all validly tendered shares for payment.
- Following the tender offer, a merger was completed on May 14, 2026, making Apellis a wholly owned subsidiary of Biogen.
- This filing serves as an exit filing for Biogen regarding its stake in Apellis Pharmaceuticals.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a positive development, reflecting strategic execution by Biogen in acquiring a company with potentially valuable assets, though the CVR introduces an element of future uncertainty.
Positives
- Successful completion of the acquisition of Apellis Pharmaceuticals.
- Acquisition terms included a cash payment and potential future contingent payments, providing value to Apellis shareholders.
- The merger was completed efficiently following the tender offer's success.
Future Outlook
This filing represents an exit filing for Biogen, indicating the completion of its involvement as a significant stakeholder in Apellis Pharmaceuticals.
Industry Context
StockSavvy.ai notes that this acquisition signifies continued consolidation within the biopharmaceutical sector, particularly in areas with high R&D potential. Biogen's move to acquire Apellis, a company focused on complement C3 inhibitors, suggests a strategic expansion into new therapeutic areas or a strengthening of its existing pipeline.
Stakeholder Impact
- Shareholders of Apellis Pharmaceuticals have received the specified cash and CVRs, concluding their investment in the company.
- Biogen Inc. has expanded its portfolio and operational scope through the acquisition.
Next Steps
- Apellis Pharmaceuticals will now operate as a wholly owned subsidiary of Biogen Inc.
Key Dates
| Date | Description |
|---|---|
| 04/06/2026 | Original Schedule 13D filing by Biogen Inc. |
| 03/31/2026 | Date Biogen entered into the Agreement and Plan of Merger with Apellis. |
| 04/14/2026 | Commencement date of the tender offer by Biogen's subsidiary, Aspen Purchaser Sub, Inc. |
| 05/14/2026 | Date Purchaser irrevocably accepted for payment all validly tendered shares and the merger was consummated. |
Recommendation
holdThis filing primarily details the completion of an acquisition and serves as an exit filing for Biogen's Schedule 13D. It does not provide new operational or financial performance data for either company that would warrant a change in investment recommendation based solely on this document. Investors should refer to separate filings for ongoing performance analysis of Biogen.
Keywords
Apellis Pharmaceuticals, Biogen Inc., Merger, Acquisition, Tender Offer, Schedule 13D, Contingent Value Right, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.